Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants-Reference-Cited by-同舟云学术

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants

Published:2021-09-09 Issue:19 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Ferrari Mathieu¹^ORCID,Mekkaoui Leila¹,Ilca F. Tudor¹,Akbar Zulaikha¹,Bughda Reyisa¹,Lamb Katarina¹,Ward Katarzyna¹,Parekh Farhaan¹,Karattil Rajeev¹,Allen Christopher¹,Wu Philip¹,Baldan Vania¹,Mattiuzzo Giada²,Bentley Emma M.²,Takeuchi Yasuhiro²³,Sillibourne James¹,Datta Preeta¹,Kinna Alexander¹,Pule Martin¹,Onuoha Shimobi C.¹

Affiliation:

1. Autolus Limited, The MediaWorks, London, United Kingdom

2. National Institute for Biological Standards and Control, Herts, United Kingdom

3. Division of Infection and Immunity, University College London, London, United Kingdom

Abstract

Mutational drift of SARS-CoV-2 risks rendering both therapeutics and vaccines less effective. Receptor decoy strategies utilizing soluble human ACE2 may overcome the risk of viral mutational escape since mutations disrupting viral interaction with the ACE2 decoy will by necessity decrease virulence, thereby preventing meaningful escape.

Funder

UK Research and Innovation

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.00685-21

Reference49 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

3. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China